International journal of radiation oncology, biology, physics
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation Study.
High-dose-rate brachytherapy boost plus external beam radiation therapy is an established option for intermediate-risk prostate cancer (PCa). Stereotactic body radiation therapy (SBRT) boost can potentially mimic high-dose-rate boost and could be a viable alternative. Here we report the long-term outcomes of a phase 1 dose-escalation trial of single-fraction SBRT boost. ⋯ Other than a grade 4 toxicity, which may in part be due to repeated biopsies of a rectal ulcer, single-fraction SBRT boost was feasible and well tolerated. Larger studies are warranted to better document the outcomes of such an approach.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2019
Gender, Professional Experiences, and Personal Characteristics of Academic Radiation Oncology Chairs: Data to Inform the Pipeline for the 21st Century.
Understanding the pathways and gateways to leadership and challenges faced by individuals in such roles can inform efforts to promote diversity and equity. We sought to describe the professional experiences and personal characteristics of academic radiation oncology (RO) chairs and to evaluate whether differences exist by gender. ⋯ Female RO chairs are as equally qualified as men in terms of productivity or leadership skills, but they face distinct challenges in the context of a gender-structured society. The observation of higher grant funding among women at the time of chair appointment suggests a possible need for interventions such as unconscious bias training to ensure that selection processes do not unnecessarily hold women to a higher standard.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2019
Quality at the American Society for Radiation Oncology Annual Meeting: Gender Balance Among Invited Speakers and Associations with Panel Success.
The American Society for Radiation Oncology (ASTRO) annual meeting is the most prominent international conference in radiation oncology. It represents one of the greatest time efforts for ASTRO volunteers, and the quality of the annual meeting is a high priority. Measures of diversity have been linked with quality of academic efforts. We conducted a study of gender diversity of the ASTRO invited speakers, focusing on speaker and panel characteristics, and associations of these characteristics with measures of audience satisfaction. ⋯ Given observations that women constitute a minority of invited speakers and that greater female representation correlates with a key panel success metric, efforts to ensure greater diversity of those included in AM speaking invitations merit serious attention.
-
Int. J. Radiat. Oncol. Biol. Phys. · Aug 2019
Five-Year Outcomes of a Single-Institution Prospective Trial of 19-Gy Single-Fraction High-Dose-Rate Brachytherapy for Low- and Intermediate-Risk Prostate Cancer.
To update outcome and toxicity results of a prospective trial of 19-Gy single-fraction high-dose-rate (HDR) brachytherapy for men with low- and intermediate-risk prostate cancer. ⋯ With extended follow-up, toxicity rates after single-fraction 19-Gy HDR brachytherapy remain low. Higher-than-expected rates of biochemical and local failure, however, raise concerns regarding the adequacy of this dose. Additional investigation to define the optimal single-fraction HDR brachytherapy dose is warranted, and single-fraction treatment currently should not be offered outside the context of a clinical trial.